1 citations
,
September 2023 in “Journal of the American Academy of Dermatology” This abstract introduces baricitinib as an approved treatment for adults with severe alopecia areata in the US, Europe, and Japan, but does not report any specific study results or findings.
20 citations
,
January 2017 in “Experimental Dermatology” In this study, deleting the Igf1 receptor in specific skin cells of mice affected hair follicle cycling but not overall skin health, suggesting Igf1r's role in hair cycle regulation through Bmp-4 activation.
29 citations
,
April 2000 in “Journal of histochemistry and cytochemistry/The journal of histochemistry and cytochemistry” This study found that ICAM-1 expression in murine skin is developmentally regulated and crucial for skin and hair follicle remodeling beyond its recognized role in immune responses.
3 citations
,
April 2019 in “The journal of investigative dermatology/Journal of investigative dermatology” This research suggests that innate lymphoid cells type 1 (ILC1) may contribute to the development of alopecia areata, alongside CD8+ T cells, by disrupting hair follicle immune privilege and promoting features of the disease.
1 citations
,
August 2021 in “Journal of The American Academy of Dermatology” In this study, baricitinib treatment led to significant regrowth of scalp, eyebrow, and eyelash hair in alopecia areata patients compared to placebo, with higher effectiveness seen at the 4-mg dose.
May 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” This study found that baricitinib can counteract the cytokine-driven reduction of the enzyme PADI1 in human keratinocytes, which may help improve skin barrier function in atopic dermatitis by enabling epidermal differentiation.
1 citations
,
March 2023 in “Anais Brasileiros de Dermatologia” November 2022 in “Journal of Investigative Dermatology” This study found that ILC1-like cells can induce alopecia areata in healthy human hair follicles, challenging the traditional belief that the disease is primarily driven by CD8+ T cells.
136 citations
,
April 2013 in “Clinical Cancer Research” The study found that IPI-926 was well tolerated up to 160 mg once daily for 28-day cycles and showed activity as a single-agent treatment in Hedgehog pathway inhibitor-naïve patients with basal cell carcinoma.
September 2023 in “Journal of The American Academy of Dermatology” In this study, baricitinib was evaluated for its effectiveness in promoting concurrent regrowth of scalp hair, eyebrows, and eyelashes in patients with severe alopecia areata, showing clinically meaningful responses compared to placebo.
1 citations
,
August 2021 in “Journal of Investigative Dermatology” ASLAN004 was safe and well-tolerated, supporting further development for treating certain diseases.
October 2024 in “The American Journal of Gastroenterology” This study described a case where both alopecia universalis and Crohn's ileitis in a 23-year-old man showed remarkable improvement with the JAK1 inhibitor upadacitinib, highlighting its potential as a treatment for patients with concurrent conditions.
October 2020 in “The American journal of gastroenterology” This case study reports a previously undescribed cause of drug-induced autoimmune hepatitis triggered by para-aminobenzoic acid (PABA), emphasizing the need for caution with this supplement.
Ivarmacitinib effectively regrows hair in severe alopecia areata.
30 citations
,
August 1993 in “PubMed” This study found that IL-1 alpha inhibits the growth of cultured human hair follicles and hair fibers, suggesting a potential role in inflammatory hair loss conditions like alopecia areata.
184 citations
,
February 2015 in “EBioMedicine” This study observed that baricitinib treatment led to significant improvement in a patient's alopecia areata symptoms and suggests further clinical trials to explore its potential as a treatment.
September 2019 in “Journal of Investigative Dermatology” This study suggests that in alopecia areata, innate lymphoid cells type 1 may contribute to the disease’s pathogenesis by inducing hair follicle changes similarly to CD8+ T cells.
January 2007 in “Journal of Southwest University” This study identified that the ND1 gene sequence of the Asian black bear's Sichuan subspecies shares high similarity with those of other bear species, raccoons, and Ailurus fulgens.
4 citations
,
September 2022 in “Journal of The American Academy of Dermatology” This study examined phase 3 clinical trial data and found that baricitinib improves hair regrowth in adults with alopecia areata and significant scalp hair loss, with the response varying based on the severity of hair loss at the start of treatment.
1 citations
,
October 2025 in “Journal of Allergy and Clinical Immunology” A JAK1 variant causes hair loss, skin issues, and thyroid disease, but treatment with a specific inhibitor can help.
August 2017 in “Seoul National University Open Repository (Seoul National University)” The study investigated the role of Aminoacyl-tRNA synthetase interacting multifunctional protein 1 (AIMP1) in hair follicle stem cell proliferation and its potential as a treatment for alopecia. AIMP1, when dissociated from the multi-tRNA synthetase complex, was found to be secreted by dermal papilla cells in a sonic hedgehog (Shh) signal-dependent manner. This secretion increased the proliferation of CD34+ hair follicle stem cells by promoting the wnt signaling pathway through inhibition of sFRP1, a known wnt antagonist. The research demonstrated that the N-terminal fragment of AIMP1 could be developed into a therapeutic peptide for hair loss. When applied topically to depilated mice, this peptide significantly accelerated hair growth, especially when formulated with carbomer. The findings highlighted a novel mechanism of AIMP1 action and its potential application in alopecia treatment.
January 2025 in “Skin Health and Disease” In this report, oral baricitinib improved both alopecia areata and immune thrombocytopenia in a 56-year-old patient, suggesting a potential dual benefit for these conditions, although regular platelet monitoring and hematology consultation are recommended.
35 citations
,
August 2010 in “The American journal of pathology” This study reports that hypomorphic alleles of the Ass1 gene in mice resemble human CTLN1, providing a potential model for preclinical studies and indicating that standard treatments for CTLN1 can rescue phenotypes.
21 citations
,
September 2021 in “New Phytologist” This study found that the transcription factor HB24 plays a critical role in root hair elongation in Arabidopsis thaliana by promoting the conversion of indole-3-butyric acid to indole-3-acetic acid through regulation of IBR1 expression.
1 citations
,
July 2022 in “British Journal of Dermatology” Baricitinib was effective in treating hair loss in adults with alopecia areata according to patient feedback.
October 2023 in “Regular and Young Investigator Award Abstracts” This study found that Baricitinib significantly reduced hair loss and immune response in a mouse model of alopecia areata.
September 2022 in “Journal of The American Academy of Dermatology” This study found that baricitinib was effective in regrowing eyebrow and eyelash hair in patients with severe alopecia areata, with similar improvements observed in both clinician-reported and patient-reported measures.
37 citations
,
April 2018 in “Journal of Allergy and Clinical Immunology” This study found that a novel IKZF1 mutation, p.L188V, is linked to juvenile-onset systemic lupus erythematosus and alters B-cell activation by disrupting normal DNA binding.
4 citations
,
November 2024 in “Journal of Advanced Research” In this study, the researchers reported that NMMHC IIA dissociates from PAR1 and activates the CREB3/ARF4 pathway, worsening thrombin-induced blood-brain barrier damage, suggesting it as a potential therapeutic target for blood-brain barrier-related diseases.
1 citations
,
November 2023 in “Journal of the European Academy of Dermatology and Venereology” Baricitinib helps with early hair regrowth in people with alopecia areata.